Background: Myxoid liposarcoma predominantly affects young and middle-aged individuals, and little is known regarding treatment tolerability and outcomes in older patients. This study aims to better understand this older patient population. Methods: This single institution retrospective study included patients aged 70 years and older with localized (non-metastatic) myxoid liposarcoma. Results: Sixteen patients were included. The median age was 75 years, and 9 (56%) were female. Fourteen (88%) were extremity tumors and two (12%) were trunk. The median tumor size was 10.4 cm (range, 3.6 to 28 cm). Five (31%) tumors had a round cell component. All patients had surgery. Fourteen (88%) had perioperative radiation, and three (19%) had perioperative chemotherapy. One patient had postoperative infection, and one patient had neutropenic fever from preoperative chemotherapy. The median follow up from surgery was 6.3 years. Eight (50%) patients died from MLPS. The median relapse-free survival and overall survival were 34 months and 75 months, respectively. Conclusions: Most older patients with localized MLPS received perioperative radiation therapy with surgery, and few serious toxicities were reported. Even with treatment, half of the patients relapsed.
背景：黏液样脂肪肉瘤主要影响中青年人群，关于老年患者治疗耐受性和预后的研究较少。本研究旨在深入了解这一老年患者群体。方法：本单中心回顾性研究纳入了70岁及以上患有局限性（非转移性）黏液样脂肪肉瘤的患者。结果：共纳入16例患者。中位年龄为75岁，其中9例（56%）为女性。14例（88%）为肢体肿瘤，2例（12%）为躯干肿瘤。中位肿瘤大小为10.4厘米（范围：3.6至28厘米）。5例（31%）肿瘤含有圆形细胞成分。所有患者均接受了手术治疗。14例（88%）接受了围手术期放疗，3例（19%）接受了围手术期化疗。1例患者出现术后感染，1例患者因术前化疗导致中性粒细胞减少性发热。术后中位随访时间为6.3年。8例（50%）患者死于黏液样脂肪肉瘤。中位无复发生存期和总生存期分别为34个月和75个月。结论：大多数局限性黏液样脂肪肉瘤老年患者接受了手术联合围手术期放疗，且严重毒性反应报道较少。尽管接受了治疗，仍有半数患者出现复发。
Tolerability and Outcomes for Treatment of Older Myxoid Liposarcoma Population
肿瘤(癌症)患者之家